- Bicara Therapeutics Inc.
Bicara Therapeutics Inc.
Website
Offer Price
Offer Size
3-Year Outlook
Volatility
1st Day Turnover
$18.00
17,500,000
Positive
High
29%
Offering Team
Deal Managers
- Morgan Stanley
- Cowen and Company
- Cantor Fitzgerald
Lawyers
- Goodwin Procter LLP
Auditors
- KPMG LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Through this dual-targeting mechanism, ficerafusp alfa has the potential to exe More
Deal Tracker
Investors
Filing
22 Aug, 2024Offer
13 Sep, 2024Look Ahead
Lock Up Expiry
13 Mar, 2025Earning
Nov 1, 2018IPO Terms
Offer Price | $18.00 |
Offer Size | 17M |